Olga Yastremska, New Africa, freepikRecombinasesDresden biotech Seamless lands up to $1.1B Eli Lilly deal for gene therapy hearing lossDresden-based experts in sequence-precise gene repair, Seamless Therapeutics, have secured a heavyweight partner. The company has entered into a global research collaboration with the world’s largest … more ➔
MarketFrom cell therapy to combat rifles: Genenta bets its future on becoming Italy’s national-security dealmakerFew biotech pivots are as jarring as Genenta’s latest move. more ➔ The Milan-based company, which went public in late 2021 on the promise of a novel cell-based gene therapy platform, is now effectively … more ➔
FundraisingUK and US venture firm Epidarex Capital announced first close fund of $145M to build life sciences start-upsThe transatlantic venture firm Epidarex Capital has reached a first close of more than $145 million (approximately €121.6 million) to focus on company creation and early-stage investments across the … more ➔
Photo of Sangharsh Lohakare from Unsplash Investment StrategyAfter decades in biotech, Gimv draws a line under new life sciences dealsBelgian investment company Gimv is drawing a clear line under one chapter of its history. The firm announced via a press release that it will stop making new investments in life sciences and instead … more ➔
ABA AustriaViennaFor €170 million: Vienna gives AI and life sciences a new homeAt a strategy retreat of the city’s political leadership, the governing parties of the City of Vienna agreed to build a new Life Science Center for Vienna – with the new AI institute AITHYRA as its … more ➔
Genmab - Photo Credit: Andrei JackametsClinical trial Genmab pauses enrollment in early ADC trial acquired from ProfoundBioGenmab has stopped enrolling patients in an early-stage clinical trial for an experimental cancer drug it gained through the acquisition of ProfoundBio in April 2024 for €1.52 billion. This pause underscores … more ➔
StatisticsUK retains Europe’s top biotech VC spot despite 2025 slowdownUK biotech is heading into 2026 with a growing sense of momentum, even as the sector continues to navigate one of the most selective investment climates in years. more ➔
LicensingLondon-based Ellipses licenses another oncologic asset from Chinese pharmaThe U.K. biotech Ellipses Pharma, which develops cancer therapeutics, announced a collaboration and licensing agreement with China-based Innolake Biopharm Co. Ltd to develop a clinical-stage, first-in-class … more ➔
Rentschler Biopharma SECDMOBoard reshuffle at RentschlerUnexpected changes at the top of Rentschler Biopharma: CEO Benedikt von Braunmühl and the Supervisory Board agreed on a swift separation in January, and COO Christiane Bardroff is also set to leave … more ➔
RestructuringIO Biotech weighs strategic options months after FDA advises against melanoma vaccine filingFour months after the FDA advised it against filing for approval of its lead melanoma vaccine, IO Biotech is preparing for further restructuring. The Copenhagen-based biotech said yesterday that it is … more ➔
Olga Yastremska, New Africa, freepik
Photo of Sangharsh Lohakare from Unsplash 
ABA Austria
Genmab - Photo Credit: Andrei Jackamets
Rentschler Biopharma SE
